[go: up one dir, main page]

MA44020A - Composés antitumoraux - Google Patents

Composés antitumoraux

Info

Publication number
MA44020A
MA44020A MA044020A MA44020A MA44020A MA 44020 A MA44020 A MA 44020A MA 044020 A MA044020 A MA 044020A MA 44020 A MA44020 A MA 44020A MA 44020 A MA44020 A MA 44020A
Authority
MA
Morocco
Prior art keywords
antitumor compounds
antitumor
compounds
Prior art date
Application number
MA044020A
Other languages
English (en)
Other versions
MA44020B1 (fr
Inventor
Marchante María Del Carmen Cuevas
Solloso Andrés Francesch
Barrasa Valentín Martínez
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MA44020A publication Critical patent/MA44020A/fr
Publication of MA44020B1 publication Critical patent/MA44020B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
MA44020A 2017-04-27 2018-04-27 Composés antitumoraux MA44020B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382228 2017-04-27
EP17382497 2017-07-26

Publications (2)

Publication Number Publication Date
MA44020A true MA44020A (fr) 2018-10-31
MA44020B1 MA44020B1 (fr) 2019-08-30

Family

ID=62063080

Family Applications (2)

Application Number Title Priority Date Filing Date
MA44020A MA44020B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux
MA44021A MA44021B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA44021A MA44021B1 (fr) 2017-04-27 2018-04-27 Composés antitumoraux

Country Status (38)

Country Link
US (5) US10538535B2 (fr)
EP (5) EP4047002B1 (fr)
JP (5) JP6501946B2 (fr)
KR (3) KR102492283B1 (fr)
CN (4) CN114751920B (fr)
AU (4) AU2018260314C1 (fr)
BR (1) BR112019022282A2 (fr)
CA (1) CA3061518A1 (fr)
CL (1) CL2019003057A1 (fr)
CO (1) CO2019011967A2 (fr)
CY (3) CY1121885T1 (fr)
DK (5) DK3615544T3 (fr)
EC (1) ECSP19083967A (fr)
ES (5) ES2740073T3 (fr)
FI (3) FI3615544T3 (fr)
HK (2) HK1255941B (fr)
HR (5) HRP20231233T1 (fr)
HU (5) HUE045641T2 (fr)
IL (3) IL289963B2 (fr)
JO (1) JOP20190254A1 (fr)
LT (5) LT4047002T (fr)
MA (2) MA44020B1 (fr)
MD (5) MD3615544T2 (fr)
ME (2) ME03466B (fr)
MX (3) MX2021016054A (fr)
MY (1) MY198004A (fr)
PH (1) PH12019550224A1 (fr)
PL (5) PL3395820T3 (fr)
PT (2) PT3395821T (fr)
RS (5) RS59174B1 (fr)
SG (2) SG10201913300YA (fr)
SI (5) SI3395821T1 (fr)
SM (5) SMT202300160T1 (fr)
TN (2) TN2019000210A1 (fr)
TW (3) TW202344509A (fr)
UY (1) UY37706A (fr)
WO (1) WO2018197663A1 (fr)
ZA (1) ZA201907119B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
KR20220119618A (ko) * 2019-11-21 2022-08-30 파르마 마르, 에스.에이. 루비넥테딘 제형으로 소세포폐암을 치료하는 방법
MX2022013298A (es) 2020-04-21 2022-11-30 Pharma Mar Sa Conjugados de anticuerpos de farmacos.
WO2021218896A1 (fr) * 2020-04-26 2021-11-04 江苏恒瑞医药股份有限公司 Dérivé de l'ecteinascidine, son procédé de préparation et son utilisation médicale
MX2023013715A (es) 2021-05-19 2024-03-26 Pharma Mar Sa Regímenes de dosis de ecubectedina.
WO2024186263A1 (fr) * 2023-03-07 2024-09-12 Axcynsis Therapeutics Pte. Ltd. Conjugués anticorps-médicament comprenant de la trabectédine et des dérivés de lurbinectédine

Family Cites Families (220)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3205220A (en) 1961-10-26 1965-09-07 Lilly Co Eli Leurosidine and leurocristine and their production
US4762949A (en) 1979-06-20 1988-08-09 University Of Illinois Foundation Acyl and carbamimidoyl alkanediamines
GB2058047B (en) 1979-07-11 1983-09-21 Asahi Chemical Ind Amides and amidines
FR2461995A1 (fr) 1979-07-20 1981-02-06 Lcc Cice Cie Europ Compo Elect Transducteur magneto-electrique pour systeme d'enregistrement magnetique, et systeme d'enregistrement comportant un tel transducteur
US4950649A (en) 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
US4782135A (en) 1980-09-12 1988-11-01 Board Of Trustees, University Of Illinois Composition of matter and process
US4493796A (en) 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US5137870A (en) 1980-09-12 1992-08-11 The Board Of Trustees Of The University Of Illinois Didemnins and nordidemnins
US4548814A (en) 1980-12-18 1985-10-22 The Board Of Trustees Of The University Of Illinois Composition of matter and process
JPS5922518A (ja) 1982-07-29 1984-02-04 余合住金産業株式会社 洋服タンス
IT1153974B (it) 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4855086A (en) 1982-10-15 1989-08-08 Burroughs Wellcome Co. Novel pesticides, preparation and use
US4537883A (en) 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide
JPS59225189A (ja) 1983-06-03 1984-12-18 Shionogi & Co Ltd キノナミン誘導体およびその製造法
US4631149A (en) 1983-07-25 1986-12-23 University Of Illinois Antiviral eudistomins from a marine tunicate
JPS6084288A (ja) 1983-10-13 1985-05-13 Shionogi & Co Ltd シアノキノナミンアセテ−ト類およびその製造法
US4567253A (en) 1984-02-03 1986-01-28 Tony Durst 2-Substituted derivatives of podophyllotoxin and etoposide
JPS61109717A (ja) 1984-11-02 1986-05-28 Teruhiko Beppu 抗腫瘍剤
HU201672B (en) 1984-12-28 1990-12-28 Conpharm Ab Process for producing pharmaceutical compositions comprising podophyllotoxin
US4644072A (en) 1985-04-12 1987-02-17 Bristol-Myers Company Intermediates for the production of epipodophyllotoxin and related compounds and processes for the preparation and use thereof
ATE74761T1 (de) 1985-09-20 1992-05-15 Cernitin Sa Verwendung von pflanzenpollenextrakten zur herstellung von das wachstum von tumorzellen hemmenden pharmazeutischen praeparaten und verfahren zu ihrer herstellung.
US4731377A (en) 1986-01-31 1988-03-15 Harbor Branch Oceanographic Institute, Inc. Antitumor cyclic peroxides
JP2562162B2 (ja) 1986-06-09 1996-12-11 ユニバーシティ・オブ・イリノイ エクテインアシジン７２９、７４３、７４５、７５９ａ、７５９ｂおよび７７０
US5149804A (en) 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5256663A (en) 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5089273A (en) 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
US4816450A (en) 1986-09-15 1989-03-28 Duke University Inhibition of protein kinase C by long-chain bases
US4737510A (en) 1986-09-30 1988-04-12 The Board Of Trustees Of The University Of Illinois Bioactive metabolites from the caribbean sponge agelas coniferin
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US4847246A (en) 1987-09-11 1989-07-11 Wilson George R Antiviral compositions derived from fireflies and their methods of use
FR2623504B1 (fr) 1987-11-25 1990-03-09 Adir Nouveaux derives n-(vinblastinoyl-23) d'acide amino-1 methylphosphonique, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5559145A (en) 1988-06-01 1996-09-24 Oxaco S.A. 1,2,4-trioxane derivatives
DE68903907T2 (de) 1988-09-05 1993-06-09 Sankyo Co Cyclisches peptid, seine herstellung und seine verwendung zur behandlung von cardiovasculaeren stoerungen.
WO1990005731A1 (fr) 1988-11-24 1990-05-31 University Of Queensland Macromolecules cytotoxiques
US5190876A (en) 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
CA2007507C (fr) 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine et n-methyl-sphingosine inhibiteurs de la croissance des cellules
US5583160A (en) 1989-02-03 1996-12-10 The Biomembrane Institute Methylsphingosine used to treat apoptosis
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
US4986988A (en) 1989-05-18 1991-01-22 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13
GB8922026D0 (en) 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US20030148933A1 (en) 1990-10-01 2003-08-07 Pharma Mar S.A. Derivatives of dehydrodidemnin B
US5053559A (en) 1989-12-29 1991-10-01 Oxaco S.A. Cleavage of 1,2,4-trioxanes
KR910014122A (ko) 1990-01-19 1991-08-31 디께다 가즈히꼬 에토포시드-2-디메틸아미노 화합물의 동결건조 제제
JPH0539283A (ja) 1991-01-31 1993-02-19 Suntory Ltd 新規物質Ｓ−５９９１７ａ及びその製造方法
US5721352A (en) 1991-02-19 1998-02-24 University Of Florida Research Foundation Entomopoxvirus expression system
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5336669A (en) 1991-12-10 1994-08-09 Erbamont, Inc. Cyclophosphamide monohydrate and lactose
JPH05247055A (ja) 1992-03-03 1993-09-24 Meiji Seika Kaisha Ltd スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
GB9212000D0 (en) 1992-06-05 1992-07-15 Univ Madrid Complutense New synthetic antitumoral compound
EP0655066A1 (fr) 1992-08-12 1995-05-31 PHARMACIA & UPJOHN COMPANY Inhibiteurs de proteine kinase et composes apparentes combines avec du taxol
US5756734A (en) 1992-09-11 1998-05-26 Pharmamar, S.A. Crambescidins: new antiviral and cytotoxic compounds from the sponge crambe crambe
ES2059259B1 (es) 1992-09-22 1995-10-01 Pharma Mar S A Pharmar Procedimiento de obtencion de nuevos areno (e)indoles utiles como intermedios en la sintesis de productos con actividad antitumoral.
US5580871A (en) 1992-11-20 1996-12-03 The Dupont Merck Pharmaceutical Company 4-Heteroaryl- 1,4-dihydropyridine compounds with calcium agonist and alpha1 -antagonist activity
GB9302044D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Cytotoxic compounds i
US6274551B1 (en) 1994-02-03 2001-08-14 Pharmamar, S.A. Cytotoxic and antiviral compound
GB9302046D0 (en) 1993-02-03 1993-03-24 Pharma Mar Sa Antiumoral compound-v
US5569757A (en) 1993-03-30 1996-10-29 Rinehart; Kenneth L. 9-deazaadenosine and its 5'-α-D-glycopyranoside isolated from the cyanobacterium anabaena affinis strain VS-1
GB9308111D0 (en) 1993-04-20 1993-06-02 Pharma Gen S A Active compound from a stonge
US5556777A (en) 1993-09-09 1996-09-17 Pharmamar, S.A. Immunosuppressive pharmaceutical compositions new biological activity from a marine agrobacterium sp.
US5478932A (en) 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US5462726A (en) 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
US5514708A (en) 1994-02-18 1996-05-07 Pharmamar, S.A. Cytotoxic metabolites from Myriapora truncata
US20040059112A1 (en) 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
US5681813A (en) 1994-04-06 1997-10-28 Pharma Mar, S.A. Thiodepsipeptide isolated from a marine actinomycete
ES2100124B1 (es) 1994-08-01 1998-04-01 Pharma Mar Sa Perfeccionamientos introducidos en la p.i. 9401697 por terpeno-quinonas con actividad antitumoral.
US5514705A (en) 1994-09-07 1996-05-07 Pharmamar, S.A. Epidioxymanadic acids A and B
US5523456A (en) 1994-09-29 1996-06-04 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
GB9422946D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Antineoplastic cyclolignan derivatives
GB9422947D0 (en) 1994-11-14 1995-01-04 Univ Salamanca Immunosuppressive cyclolignan derivatives
GB9504662D0 (en) 1995-03-08 1995-04-26 Pharma Mar Sa Antitumour isocoumarins
US20010039041A1 (en) 1995-06-07 2001-11-08 Pharma Mar, S.A. Immunosuppressive sesbanimide compositions and methods of treatment using same
US5661175A (en) 1995-06-20 1997-08-26 Kashman; Yoel Hemiasterlin and geodiamolide TA
US5852033A (en) 1995-06-29 1998-12-22 Pharma Mar, S.A. Methods of treatment using lamellarin-class alkaloids
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
US5681847A (en) 1995-12-05 1997-10-28 Harbor Branch Oceanographic Institution, Inc. Methods of using discodermolide compounds
EP0821068A3 (fr) 1996-03-29 1999-06-02 Rohm And Haas Company Sphinogolipides et procédé pour ceux-ci
GB9608010D0 (en) 1996-04-18 1996-06-19 Pharma Mar Sa Trunkamide A
US6156724A (en) 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
US5721362A (en) 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
AU731757B2 (en) 1996-10-24 2001-04-05 Board Of Trustees Of The University Of Illinois, The Semi-synthetic studies toward didemnin analogues
WO1998017302A1 (fr) 1996-10-24 1998-04-30 The Board Of Trustees Of The University Of Illinois Synthese totale d'analogues amino-hip de didemnine a
GB9622427D0 (en) 1996-10-28 1997-01-08 Pharma Mar Sa Antimalarial drugs
US6028077A (en) 1997-04-15 2000-02-22 Rinehart; Kenneth L. Crambescidin compounds
US6800661B1 (en) 1997-04-15 2004-10-05 Board Of Trustees Of The University Of Illinois Spisulosine compounds
US6034058A (en) 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US5985876A (en) 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
USRE38793E1 (en) 1997-04-15 2005-09-06 Rinehart Kenneth L Spisulosine compounds
US6107520A (en) 1997-04-15 2000-08-22 The Board Of Trustees Of The University Of Illinois Spisulosine compounds
AUPO656597A0 (en) 1997-05-02 1997-05-29 Australian National University, The Preparation of therapeutic compounds
ATE421329T1 (de) 1997-05-07 2009-02-15 Pharma Mar Sa Verwendung von aplidine zur behandlung von kardiovaskulären erkrankungen
GB9723206D0 (en) 1997-11-03 1998-01-07 Inst Biomar Sa New cytotoxic pyridoacridine alkaloids
GB9727301D0 (en) 1997-12-23 1998-02-25 Inst Biomar Sa Asmarine A and B: New cytotoxic alkaloids
US6420357B1 (en) 1997-12-23 2002-07-16 Instituto Biomar, S.A. Cytotoxic alkaloid derivatives including Asmarine A and B isolated from a sponge
GB9801741D0 (en) 1998-01-27 1998-03-25 Inst Biomar Sa New cytotoxic tris (oxazole)-containing macrolides
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
WO1999051238A1 (fr) 1998-04-06 1999-10-14 The Board Of Trustees Of The University Of Illinois Ecteine-ascidines semi-synthetiques
US6656948B2 (en) 1998-04-29 2003-12-02 Universidad Complutense De Madrid Cytotoxic compounds: derivatives of the pyrido[2,3,4-kl]acridine ring system
US6544560B1 (en) 1998-05-05 2003-04-08 Pharma Mar, S.A. Culture of sessile marine animals
DE69923965T2 (de) * 1998-05-11 2006-04-06 Pharma Mar, S.A., Tres Cantos Ecteinascidinderivate
GB9810998D0 (en) 1998-05-21 1998-07-22 Univ Madrid Complutense Antitumour 1,5-diazaanthraquinones
US6124292A (en) 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB9821975D0 (en) 1998-10-08 1998-12-02 Pharma Mar Sa New cytotoxic alkaloids
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MY130271A (en) 1999-05-14 2007-06-29 Pharma Mar Sa Hemisynthetic method and new compounds
GB9918178D0 (en) 2000-05-15 1999-10-06 Pharma Mar Sa Synthetic methods
GB9915069D0 (en) 1999-06-28 1999-08-25 Inst Biomar Sa New indolocarbazole alkaloids from a marine actinomycete
US6635677B2 (en) 1999-08-13 2003-10-21 Case Western Reserve University Methoxyamine combinations in the treatment of cancer
SK287762B6 (sk) 1999-11-15 2011-09-05 Pharma Mar, S. A. Použitie aplidínu na prípravu farmaceutického prostriedku na liečenie rakoviny
CA2397597A1 (fr) 2000-01-19 2001-07-26 The Trustees Of Columbia University In The City Of New York Composes de la serie saframycine-ecteinascidine, utilisations et synthese
GB0002952D0 (en) 2000-02-09 2000-03-29 Pharma Mar Sa Process for producing kahalalide F compounds
PL357193A1 (en) 2000-02-16 2004-07-26 Pharma Mar, S.A. Oxy-and amino-substituted tetrahydrofuryl derivatives with antitumour activity
US20030187075A1 (en) 2000-03-20 2003-10-02 Junichi Tanaka Keith Sponge antitumor compounds
US6509315B1 (en) 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
BR0109958A (pt) 2000-04-07 2003-05-27 Univ Pennsylvania Análogos de didemnina e tamandarina e métodos de preparação e uso deles
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
PL210703B1 (pl) 2000-04-12 2012-02-29 Pharma Mar Związek ekteinascydynowy, kompozycja farmaceutyczna oraz zastosowanie związku ekteinascydynowego
GB0010799D0 (en) 2000-05-04 2000-06-28 Inst Biomar Sa Stolonoxides
MXPA02011319A (es) * 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
US7420051B2 (en) 2000-05-15 2008-09-02 Pharma Mar, S.A. Synthetic process for the manufacture of an ecteinaschidin compound
GB0011927D0 (en) 2000-05-17 2000-07-05 Inst Biomar Sa New use of citreamicins
IL153096A0 (en) 2000-06-06 2003-06-24 Pharma Mar Sa Spisulosine analogs and pharmaceutical compositions containing the same
GB0016020D0 (en) 2000-06-29 2000-08-23 Inst Biomar Sa New polyciclic xanthones and their use
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
CA2414200C (fr) 2000-07-11 2010-05-04 Pharma Mar, S.A. Derives de varioline agissant comme agents anti-cancereux
EP2275174B1 (fr) 2000-07-13 2016-04-20 ReCor Medical, Inc. Appareil de traitement thermique avec application d'énergie ultrasonique
GB0019117D0 (en) 2000-08-03 2000-09-27 Univ Barcelona Derivatives of variolin B
US7507766B2 (en) 2000-10-12 2009-03-24 Pharma Mar, S.A. Treatment of cancers
HUP0302293A3 (en) 2000-10-12 2006-04-28 Pharma Mar Sa Treatment of cancers by aplidine in conjunction with a myoprotector
AU2002210749B2 (en) 2000-10-31 2006-12-21 Pharma Mar, S.A. Kahalalide F formulation
IL155781A0 (en) 2000-11-06 2003-12-23 Pharma Mar Sa Effective antitumor treatments
GB0030417D0 (en) 2000-12-13 2001-01-24 Pharma Mar Sa An anticancer lead compound isolated from a New Zealand ascidian
CA2435418A1 (fr) 2001-01-24 2002-08-01 Mestex Ag Utilisation de substances neurotoxiques pour la production d'un agent servant a traiter les douleurs articulaires
IL156580A0 (en) 2001-01-25 2004-01-04 Bristol Myers Squibb Co A method for formulating an epothilone analog for parenteral use and pharmaceutical preparations including an epothilone analog
WO2002064843A1 (fr) 2001-02-09 2002-08-22 The Regents Of The University Of California Composes de la famille de l'ecteinascidine: compositions et procedes
GB0105745D0 (en) 2001-03-08 2001-04-25 Pharma Gen S A Immobilisation of ligands
GB0108234D0 (en) 2001-04-02 2001-05-23 Pharma Mar Sa Process for producing trunkamide A compounds
GB0116966D0 (en) 2001-07-11 2001-09-05 Pharma Mar Sa Anittumoral compounds
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0119243D0 (en) 2001-08-07 2001-10-03 Pharma Mar Sa Antitumoral analogs of ET-743
EP1435991B1 (fr) 2001-10-19 2008-10-15 Pharma Mar, S.A. Utilisation d'aplidine pour le traitement du cancer du pancreas
EP1435990A1 (fr) 2001-10-19 2004-07-14 Pharma Mar, S.A. Composes a base de kahalalide utilisables en therapie anticancereuse
EP1435988A4 (fr) 2001-10-19 2008-01-09 Pharmamar Sa Utilisation amelioree de compose anti-tumoral dans le traitement des cancers
US20050054555A1 (en) 2001-10-19 2005-03-10 Jose Jimeno Kahalalide compounds for use in cancer therapy
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
US20040019027A1 (en) 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0217638D0 (en) 2002-07-30 2002-09-11 Pharma Mar Sa Total synthesis of myriaporones
WO2004010957A2 (fr) 2002-07-31 2004-02-05 Seattle Genetics, Inc. Conjugues de medicaments et leur utilisation dans le traitement du cancer, d'une maladie auto-immune ou d'une maladie infectieuse
GB0218813D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa DNA sequences from an endosymbiont and their uses
GB0218816D0 (en) 2002-08-13 2002-09-18 Pharma Mar Sa Antitumoral analogs of lamellarins
US20040033940A1 (en) 2002-08-16 2004-02-19 Pharma Mar, S.A. Cyclic hepta-peptide derivative from colonial ascidians, lissoclinum SP
GB0304367D0 (en) 2003-02-26 2003-04-02 Pharma Mar Sau Methods for treating psoriasis
ES2357644T3 (es) 2002-10-18 2011-04-28 Pharma Mar, S.A.U. Compuesto 4-metilhexanoico kahalalido f.
GB0229793D0 (en) 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
DE602004027888D1 (de) 2003-02-20 2010-08-12 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihr
GB0303940D0 (en) 2003-02-20 2003-03-26 Pharma Mar Sau Solid phase synthesis of antitumoral compounds
US7507708B2 (en) 2003-02-26 2009-03-24 Pharma Mar, S.A.U. Antitumoral compounds
RU2341283C2 (ru) 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей
RU2335294C2 (ru) 2003-03-12 2008-10-10 Дана-Фарбер Кэнсер Инститьют, Инк. Аплидин для лечения множественной миеломы
EP1613338A4 (fr) 2003-03-21 2009-06-24 Madeleine M Joullie Analogues de tamandarin , fragments associes et leurs methodes d'elaboration et d'utilisation
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
GB0312407D0 (en) 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
US20060019256A1 (en) 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
GB0314726D0 (en) 2003-06-24 2003-07-30 Inst Biomar Sa New cytotoxic depsipeptides
CA2533335A1 (fr) 2003-07-25 2005-02-17 Novartis Ag Lactames substitues et utilisation de ceux-ci en tant qu'agents anti-cancereux
GB0321066D0 (en) 2003-09-09 2003-10-08 Pharma Mar Sau New antitumoral compounds
ATE419242T1 (de) 2003-10-09 2009-01-15 Abbott Lab Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
GB0324201D0 (en) 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
JP2007511499A (ja) 2003-11-13 2007-05-10 ファーマ・マール・エス・アー・ウー コンビネーション
GB0326486D0 (en) 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
CA2545054A1 (fr) * 2003-11-14 2005-06-02 Pharma Mar, S.A. Therapie anticancer utilisant une combinaison de et-743 et de paclitaxel
DE102004011809A1 (de) 2004-03-11 2005-09-29 Robert Bosch Gmbh Magnetsensoranordnung
GB0408958D0 (en) 2004-04-22 2004-05-26 Pharma Mar Sa Convergent synthesis for kahalalide compounds
WO2005118584A2 (fr) 2004-05-26 2005-12-15 Axys Pharmaceuticals, Inc. Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
CA2573072A1 (fr) 2004-07-09 2006-01-19 Rafael Rosell Costa Marqueurs moleculaires de pronostic
US20080242670A2 (en) 2004-09-29 2008-10-02 Pharma Mar S.A., Sociedad Unipersonal Anti-Inflammatory Agents
ES2326825T3 (es) 2004-10-26 2009-10-20 Pharma Mar S.A., Sociedad Unipersonal Doxorubicina liposomal pegilada en combinacion con ecteinascidina 743.
RS50510B (sr) 2004-10-29 2010-03-02 Pharma Mar S.A., Sociedad Unipersonal Formulacije koje sadrže ekteinascidin i disaharid
JP4993645B2 (ja) 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
WO2006066183A2 (fr) 2004-12-16 2006-06-22 Axys Pharmaceuticals, Inc. Nouveaux analogues de saframycine utilises en tant qu'agents therapeutiques
JP2008540362A (ja) 2005-05-03 2008-11-20 ファルマ、マール、ソシエダード、アノニマ 抗腫瘍性テトラヒドロピリミジン
GB0515673D0 (en) 2005-08-01 2005-09-07 Pharma Mar Sa Antitumoral compounds
RU2008107974A (ru) 2005-08-02 2009-09-10 Фарма Мар, С.А. (Es) Гены, участвующие в биосинтезе тиокоралина и его гетерологичном продуцировании
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0523098D0 (en) 2005-11-14 2005-12-21 Pharma Mar Sa Antitumoral compounds
ES2361566T3 (es) 2005-11-25 2011-06-20 Pharma Mar S.A., Sociedad Unipersonal Uso de inhibidores de parp-1.
ES2276629B1 (es) 2005-12-15 2009-04-01 Pharma Mar, S.A. Compuestos antitumorales.
ES2288107B1 (es) 2006-01-27 2008-11-01 Fundacion Imabis Instituto Mediterraneo Para El Avance De La Biotecnologia Y La Investigacion Sanita Derivados aciclicos saturados e insaturados de cadena larga de sulfamidas como activadores especificos de receptores ppar-alfa.
EP2029155B1 (fr) 2006-02-28 2016-04-13 Pharma Mar S.A. L'amélioration du traitement du myélome multiple
MX2008014404A (es) 2006-05-12 2008-11-27 Pharma Mar Sa Tratamientos anticancer con combinacion de docetaxel y ecteinascidin.
EP1864682A1 (fr) 2006-06-09 2007-12-12 Sanofi-Aventis Dérivés de la Leptomycine
EP2404913A3 (fr) 2006-06-16 2012-06-06 Pharma Mar S.A. Procédé et intermédiaires pour la préparation de composés antitumoraux de dihydropyran-2-one
WO2009050303A1 (fr) 2007-10-19 2009-04-23 Pharma Mar, S.A. Marqueurs moléculaires pronostiques pour le traitement par et-743
CA2703720A1 (fr) 2007-10-19 2009-04-23 Albert Einstein College Of Medicine Of Yeshiva University Traitements antitumoraux ameliores
JP2011500650A (ja) 2007-10-19 2011-01-06 ファルマ・マール・ソシエダード・アノニマ 改良された抗腫瘍治療
CA2708080C (fr) 2007-12-14 2016-06-14 Pharma Mar, S.A. Composes antitumoraux
MY148651A (en) 2007-12-20 2013-05-15 Pharma Mar Sa Antitumoral compounds
EP2252315A1 (fr) 2008-01-30 2010-11-24 Pharma Mar, S.A. Traitements antitumoraux améliorés
WO2009111698A1 (fr) 2008-03-07 2009-09-11 Pharma Mar, S.A. Traitements améliorés contre le cancer
KR20100126479A (ko) 2008-03-07 2010-12-01 파르마 마르 에스.에이. 개선된 항종양 치료법들
MX2010012358A (es) 2008-05-16 2011-01-25 Pharma Mar Sa Tratamientos para el mieloma multiple.
EP2307003A2 (fr) 2008-05-16 2011-04-13 Pharma Mar S.A. Thérapie combinée comportant un alcaloïde antitumoral
RS58724B1 (sr) 2008-05-23 2019-06-28 Wyeth Llc Jedinjenja triazina kao inhibitori pi3 kinaze i mtor
CN102083840A (zh) 2008-07-03 2011-06-01 马尔药品公司 抗肿瘤大环内酯类化合物
CA2727915C (fr) 2008-07-15 2016-04-26 Genentech, Inc. Conjugues de derives d'anthracycline, procede de preparation associe et utilisation comme composes antitumoraux
US20110105409A1 (en) 2008-07-17 2011-05-05 Pharma Mar, S.A. Anticancer Compounds
US20110237520A1 (en) 2008-12-19 2011-09-29 Pharma Mar, Sa Anticancer Compounds
WO2010149688A2 (fr) 2009-06-24 2010-12-29 Pharma Mar, S.A. Composés anticancéreux
MY162934A (en) 2010-04-27 2017-07-31 Pharma Mar Sa Anticancer steroidal lactones unsaturated in position 7 (8)
AU2011257277B2 (en) * 2010-05-25 2016-02-25 Pharma Mar, S.A. Synthetic process for the manufacture of ecteinascidin compounds
EP2786753B1 (fr) 2010-11-12 2019-01-09 Pharma Mar S.A. Thérapie de combinaison avec un antibiotique antitumoral
DE102012211024B4 (de) 2012-06-27 2024-10-24 Robert Bosch Gmbh Verfahren zum Betreiben eines Fahrzeuges
JP5922518B2 (ja) 2012-07-20 2016-05-24 浜松ホトニクス株式会社 シンチレータパネル及び放射線検出器
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
JP2019524716A (ja) 2016-07-14 2019-09-05 ファイザー・インク バニン１酵素の阻害薬としての新規のピリミジンカルボキサミド
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物

Also Published As

Publication number Publication date
JP2020517709A (ja) 2020-06-18
CN110621678B (zh) 2024-09-20
ES2944579T3 (es) 2023-06-22
LT3395820T (lt) 2019-08-12
EP4101855A1 (fr) 2022-12-14
KR20220109495A (ko) 2022-08-04
FI4101855T3 (fi) 2023-09-22
TW202202509A (zh) 2022-01-16
HUE062157T2 (hu) 2023-10-28
MD4047002T2 (ro) 2023-08-31
DK4101855T3 (da) 2023-11-06
AU2022200250C1 (en) 2022-06-23
BR112019022282A2 (pt) 2020-05-19
CY1121884T1 (el) 2020-10-14
AU2018260314C1 (en) 2022-04-21
CN117865987A (zh) 2024-04-12
JP7186723B2 (ja) 2022-12-09
TN2019000211A1 (en) 2021-01-07
JP7422812B2 (ja) 2024-01-26
EP3615544B9 (fr) 2024-01-03
PL3615544T3 (pl) 2023-07-17
EP4047002B1 (fr) 2023-03-08
ES2741901T3 (es) 2020-02-12
IL270153B2 (en) 2023-10-01
US11332480B2 (en) 2022-05-17
LT3615544T (lt) 2023-05-10
DK3615544T3 (da) 2023-05-30
LT3395821T (lt) 2019-08-12
MX2021016054A (es) 2022-06-01
EP3615544A1 (fr) 2020-03-04
MA44020B1 (fr) 2019-08-30
MD3395821T2 (ro) 2019-10-31
PL3395820T3 (pl) 2019-11-29
PL4101855T3 (pl) 2023-12-27
HUE063736T2 (hu) 2024-01-28
US11339180B2 (en) 2022-05-24
CN114751920B (zh) 2024-06-07
IL289963B2 (en) 2023-10-01
IL289963B1 (en) 2023-06-01
SMT202300343T1 (it) 2023-11-13
HRP20191442T1 (hr) 2019-11-15
US20180312529A1 (en) 2018-11-01
RS64686B1 (sr) 2023-11-30
CY1121885T1 (el) 2020-10-14
US20220242883A1 (en) 2022-08-04
MX2019012812A (es) 2020-01-14
ZA201907119B (en) 2021-07-28
HUE046109T2 (hu) 2020-02-28
EP3395821A1 (fr) 2018-10-31
ECSP19083967A (es) 2019-12-27
JOP20190254A1 (ar) 2019-10-27
MX2021016058A (es) 2022-02-03
CN114736219B (zh) 2024-06-07
HRP20191443T1 (hr) 2019-11-15
AU2022200249C1 (en) 2022-06-23
IL295044B1 (en) 2023-07-01
SG11201909841RA (en) 2019-11-28
EP3395821B1 (fr) 2019-05-15
CN114751920A (zh) 2022-07-15
US11713325B2 (en) 2023-08-01
WO2018197663A1 (fr) 2018-11-01
UY37706A (es) 2018-11-30
HK1255938B (zh) 2020-04-29
DK3395820T3 (da) 2019-08-12
JP2018188432A (ja) 2018-11-29
JP7490835B2 (ja) 2024-05-27
SMT201900447T1 (it) 2019-09-09
FI3615544T3 (fi) 2023-05-23
PT3395821T (pt) 2019-08-27
HUE045641T2 (hu) 2020-01-28
CN114736219A (zh) 2022-07-12
HK1255941B (zh) 2020-04-29
ES2740073T3 (es) 2020-02-05
TN2019000210A1 (en) 2021-01-07
TW201906850A (zh) 2019-02-16
EP4047002A1 (fr) 2022-08-24
EP3615544B1 (fr) 2023-03-22
HRP20230455T1 (hr) 2023-07-21
EP4101855B1 (fr) 2023-08-02
TWI742273B (zh) 2021-10-11
MD3395820T2 (ro) 2019-10-31
HRP20230433T1 (hr) 2023-07-07
CL2019003057A1 (es) 2020-02-21
IL289963A (en) 2022-03-01
SI3395820T1 (sl) 2019-09-30
JP2023052597A (ja) 2023-04-11
MA44021A (fr) 2019-05-15
CN110621678A (zh) 2019-12-27
AU2022200250B1 (en) 2022-02-10
US20210070775A1 (en) 2021-03-11
LT4047002T (lt) 2023-05-10
ES2944344T3 (es) 2023-06-20
IL295044B2 (en) 2023-11-01
DK3395821T3 (da) 2019-08-19
MD4101855T2 (ro) 2023-12-31
KR102492283B1 (ko) 2023-01-27
IL270153A (fr) 2019-12-31
RS64200B1 (sr) 2023-06-30
IL295044A (en) 2022-09-01
AU2022201657A1 (en) 2022-03-31
PT3395820T (pt) 2019-08-07
AU2022200249B1 (en) 2022-02-10
RS64174B1 (sr) 2023-05-31
PL4047002T3 (pl) 2023-07-24
DK4047002T3 (da) 2023-05-01
KR20210126791A (ko) 2021-10-20
SI4101855T1 (sl) 2024-03-29
US20210246146A1 (en) 2021-08-12
SG10201913300YA (en) 2020-03-30
KR20200012846A (ko) 2020-02-05
IL270153B1 (en) 2023-06-01
AU2018260314A1 (en) 2019-10-31
ME03467B (fr) 2020-01-20
TWI807411B (zh) 2023-07-01
JP6501947B2 (ja) 2019-04-17
TW202344509A (zh) 2023-11-16
SI4047002T1 (sl) 2023-07-31
US20240166666A1 (en) 2024-05-23
RS59174B1 (sr) 2019-10-31
SMT202300169T1 (it) 2023-07-20
SI3615544T1 (sl) 2023-07-31
CO2019011967A2 (es) 2020-02-18
EP3395820B1 (fr) 2019-05-15
HUE062032T2 (hu) 2023-09-28
LT4101855T (lt) 2023-08-25
ME03466B (fr) 2020-01-20
AU2018260314B2 (en) 2021-12-09
KR102491180B1 (ko) 2023-01-20
HRP20231233T1 (hr) 2024-01-19
PH12019550224A1 (en) 2020-10-12
US10538535B2 (en) 2020-01-21
EP4101855B9 (fr) 2024-01-03
MA44021B1 (fr) 2019-08-30
SI3395821T1 (sl) 2019-09-30
MD3615544T2 (ro) 2023-08-31
CY1126061T1 (el) 2023-11-15
JP2022130682A (ja) 2022-09-06
RS59173B1 (sr) 2019-10-31
MY198004A (en) 2023-07-25
JP2018188431A (ja) 2018-11-29
ES2960063T3 (es) 2024-02-29
KR102510975B1 (ko) 2023-03-16
FI4047002T3 (fi) 2023-05-22
PL3395821T3 (pl) 2019-10-31
SMT201900448T1 (it) 2019-09-09
EP3395820A1 (fr) 2018-10-31
JP6501946B2 (ja) 2019-04-17
SMT202300160T1 (it) 2023-07-20
CA3061518A1 (fr) 2018-11-01

Similar Documents

Publication Publication Date Title
EP3720430A4 (fr) Composés benzocarbonyle
EP3691623A4 (fr) Composés de benzosulfonyle
MA47131A (fr) Composés benzyl-amide phosphodiamide antiviraux
MA49701A (fr) Composés immunomodulateurs
MA41614A (fr) Composés antiviraux
MA52948A (fr) Composés
MA42293A (fr) Composés antibactériens
EP3609871A4 (fr) Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
MA51669A (fr) Composés
MA53003A (fr) Composés
EP3464336A4 (fr) Composés
MA44020A (fr) Composés antitumoraux
DK4039675T3 (da) Phenyl-2-hydroxy-acetylamino-2-methyl-phenyl forbindelser
EP3718545A4 (fr) Agent antitumoral
MA50504A (fr) Composés antibactériens
MA49621A (fr) Composés bifonctionnels
MA49522A (fr) Nouveaux composés de quinoléinone
MA52946A (fr) Composés
EP3405455A4 (fr) Composés de 2-oxindole
MA49880A (fr) Composés anticancéreux
MA51221A (fr) Composés de pyrazolopyridinone
EP3713941A4 (fr) Composés de pyrazolopyridinone
DK3672941T3 (da) Pyridylpyridonforbindelser
MA49885A (fr) Composés macrocycliques
EP3504269A4 (fr) Composés de fluoroélastomère